Taking advantage of the US FDA's decision to grant a breakthrough therapy designation for its lead drug candidate drisapersen in partnership with GlaxoSmithKline, Dutch biotechnology firm Prosensa priced its US initial public offering at $13 per share for gross proceeds of $78 million.
Breakthrough status in hand, Prosensa launches $78m IPO
Taking advantage of the US FDA's decision to grant a breakthrough therapy designation for its lead drug candidate drisapersen in partnership with GlaxoSmithKline, Dutch biotechnology firm Prosensa priced its US initial public offering at $13 per share for gross proceeds of $78 million.
More from Musculoskeletal
More from Therapy Areas
• By
Evaluate's top five unpartnered clinical oncology assets reveals you have to get in early to snap up innovation in the competitive cancer space.
• By
The agency loosened requirements for echocardiograms and removed contraindications for a number of commonly used drugs.
• By
The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.